Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16.98 USD | +1.43% | -3.96% | +55.07% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 800K | Capitalization | 633M |
---|---|---|---|---|---|
Net income 2024 * | -158M | Net income 2025 * | -241M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 791 x |
P/E ratio 2024 * |
-4.16
x | P/E ratio 2025 * |
-2.83
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | +1.43% | ||
1 week | -3.96% | ||
Current month | +1.43% | ||
1 month | +45.63% | ||
3 months | +50.67% | ||
6 months | +71.52% | ||
Current year | +55.07% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 12-03-31 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 20-05-31 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 20-05-31 |
David Hallal
CHM | Chairman | 56 | 18-05-31 |
Director/Board Member | 52 | 18-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 28 M€ | -1.28% |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 16.98 | +1.43% | 296,414 |
24-05-31 | 16.74 | -2.39% | 368,666 |
24-05-30 | 17.15 | -1.10% | 222,784 |
24-05-29 | 17.34 | +1.52% | 222,181 |
Delayed Quote Nasdaq, June 03, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+55.07% | 633M | |
+15.55% | 121B | |
+12.66% | 107B | |
-2.53% | 24.82B | |
+0.99% | 22.48B | |
-9.47% | 18.32B | |
-42.28% | 16.33B | |
-18.92% | 15.31B | |
+6.19% | 14.08B | |
+28.83% | 11.74B |
- Stock Market
- Equities
- ITOS Stock